Metagenomi, Inc. MGX
We take great care to ensure that the data presented and summarized in this overview for Metagenomi, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MGX
Top Purchases
Top Sells
About MGX
Insider Transactions at MGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 01
2025
|
Sarah B. Noonberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+10.91%
|
-
|
|
Apr 01
2025
|
Matthew Wein |
BUY
Grant, award, or other acquisition
|
Direct |
7,425
+20.02%
|
-
|
|
Apr 01
2025
|
Jian Irish |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+6.67%
|
-
|
|
Apr 01
2025
|
Brian C. Thomas Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+1.25%
|
-
|
|
Apr 01
2025
|
Pamela Wapnick Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+15.97%
|
-
|
|
Mar 05
2025
|
Pamela Wapnick Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,808
-2.94%
|
$1,808
$1.87 P/Share
|
|
Mar 05
2025
|
Matthew Wein |
SELL
Open market or private sale
|
Direct |
930
-8.94%
|
$930
$1.87 P/Share
|
|
Dec 05
2024
|
Pamela Wapnick Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,559
-2.47%
|
$1,559
$1.86 P/Share
|
|
Sep 05
2024
|
Pamela Wapnick Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,265
-9.04%
|
$12,530
$2.88 P/Share
|
|
Apr 01
2024
|
Jian Irish |
BUY
Grant, award, or other acquisition
|
Direct |
70,471
+19.08%
|
-
|
|
Apr 01
2024
|
Luis Borges Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,316
+50.0%
|
-
|
|
Apr 01
2024
|
Matthew Wein |
BUY
Grant, award, or other acquisition
|
Direct |
10,397
+50.0%
|
-
|
|
Apr 01
2024
|
Pamela Wapnick Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
69,316
+50.0%
|
-
|
|
Apr 01
2024
|
Sarah B. Noonberg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,763
+36.53%
|
-
|
|
Apr 01
2024
|
Simon Harnest |
BUY
Grant, award, or other acquisition
|
Direct |
11,552
+8.61%
|
-
|
|
Apr 01
2024
|
Simren Delaney |
BUY
Grant, award, or other acquisition
|
Direct |
6,931
+6.87%
|
-
|
|
Apr 01
2024
|
Brian C. Thomas Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,992
+4.55%
|
-
|
|
Feb 13
2024
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,000
+31.51%
|
$12,000,000
$15.0 P/Share
|
|
Feb 13
2024
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
839,175
+47.19%
|
-
|
|
Feb 13
2024
|
Bayer Healthcare LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,050,997
+26.01%
|
-
|
Last 12 Months Summary
Buy / Acquisition
90.4K
Shares
From
5
Insiders
| Grant, award, or other acquisition | 90.4K shares |
|---|
Sell / Disposition
10.6K
Shares
From
2
Insiders
| Open market or private sale | 10.6K shares |
|---|